Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers

HIV Infections Clinical Trial

— EV03/ANRSVAC20  

Official title:

A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00490074
• Other study ID #: 2006-006141-13
• Secondary ID: EV03/ANRSVAC20
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 21, 2007
• Last updated: November 25, 2009
• Start date: July 2007
• Est. completion date: October 2009

Study information

• Verified date: November 2009
• Source: French National Agency for Research on AIDS and Viral Hepatitis
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Switzerland: SwissmedicUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyGermany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers. Volunteers will be vaccinated by DNA-C and NYVAC-C vaccines, and the immune changes will be assessed, as well as safety of the vaccines. Volunteers will be followed during 72 weeks.

Description:

Methods: randomised phase I/II international trial with a parallel group design, open to participants and investigators but blind to laboratory personnel, in healthy volunteers.

Vaccines strategies: 70 volunteers will receive 3 DNA-C vaccinations and 1 NYVAC-C vaccination; 70 volunteers will receive 2 DNA-C vaccinations and 2 NYVAC-C vaccination.

DNA-C: 2x2ml intra muscular in right and left vastus lateralis; NYVAC-C: 1 ml intramuscular in non-dominant deltoid.

Main outcome:

1. the presence of CD8/CD4+ T cell responses defined according to internationally agreed criteria for evaluation of IFNgamma ELISPOT assays:

• in response to env plus at least one of the gag, pol, nef peptide pools,

• at weeks 26 or 28;

2. the safety parameters.

Secondary outcomes:

• cellular responses,

• antibody responses,

• all grade 1 and 2 adverse events,

• all events including those considered unrelated.

Sample size: 140 volunteers

Enrollment period: 9 months

Patient's participation duration: 78 weeks

Study duration: 27 months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 147
• Est. completion date: October 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• age between 18 and 55 years on the day of screening

• available for follow-up for the duration of the study (78 weeks from screening)

• able to give written informed consent

• at low risk of HIV and willing to remain so for the duration of the study low risk of HIV infection defined as:

• no history of injecting drug use in the previous ten years

• no gonorrhoea or syphilis in the last six months

• no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months

• no unprotected anal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative

• no unprotected vaginal intercourse in the last six months outside a relationship with a regular known/presumed HIV negative partner

• willing to undergo a HIV test

• willing to undergo a genital infection screen

• if heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable contraceptive; IUCD; consistent record with condoms if using these; physiological or anatomical sterility in self or partner) from 14 days prior to the first vaccination until 4 months after the last, and willing to undergo urine pregnancy tests prior to each vaccination

• if heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination

• for French volunteers only :

• subjects registered in French Health ministry computerised file and authorised to participate in a clinical trial

• subjects covered by Health Insurance

• subjects included in the ANRS vaccine research network of volunteers

Exclusion Criteria:

• pregnant or lactating

• clinically relevant abnormality on history or examination including history of grand-mal epilepsy; severe eczema; allergy to eggs or gentamicin; severe allergic diseases; liver disease with inadequate hepatic function; haematological, metabolic or gastrointestinal disorders; uncontrolled infection; autoimmune disease, immunodeficiency or use of immunosuppressives in preceding 3 months

• receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of enrolment

• receipt of blood products or immunoglobin within 4 months of screening

• participation in another trial of a medicinal product, completed less than 30 days prior to enrolment

• history of severe local or general reaction to vaccination defined as

• local: extensive, indurated redness and swelling involving most of the anterolateral thigh or the major circumference of the arm, not resolving within 72 hours

• general: fever >= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours

• HIV 1/2 positive or indeterminate on screening

• positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment

• positive for DNA/ANA antibodies at titre considered clinically relevant by immunology laboratory

• grade 1 or above routine laboratory parameters (see section 4.1.4 & appendix 4 for definitions) Note of clarification 18th april 2008: hyperbilirubinemia has to be considered as an exclusion criterion only when confirmed to be conjugated bilirubinemia

• unlikely to comply with protocol

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• HIV Infections

Intervention

Biological:
• DNA-C
1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
• NYVAC-C
NYVAC-C 1 ml IM

Locations

Country	Name	City	State
France	Hôpital Henri Mondor	Créteil
Switzerland	Centre Hospitalier Universitaire Vaudois CHUV	Lausanne

Sponsors (2)

Lead Sponsor	Collaborator
French National Agency for Research on AIDS and Viral Hepatitis	EuroVacc Foundation

Countries where clinical trial is conducted

France,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity parameter: presence of CD8/CD4+ T cell responses defined according to internationally agreed criteria for evaluation of IFNgamma ELISPOT assays, in response to env plus at least one of the gag, pol, nef peptide pools		week 26 and week 28	No
Primary	Safety parameter: grade 3 or above local adverse event, grade 3 or above systemic adverse event, grade 3 or above other clinical or laboratory adverse event,any event attributable to vaccine leading to discontinuation of the immunisation regimen.		within 72 weeks	No
Secondary	Cellular responses: CD8/CD4+ T cell mean IFNgamma Spot Forming Units (SFU) per million cells across the peptide pools		at weeks 26 and 28	No
Secondary	Cellular responses: CD8/CD4+ T cell mean Spot Forming Units (SFU) per million cells across the peptide pools		at any week following the first immunisation including weeks 48 and 72	No
Secondary	Cellular responses: mean proportion of CD4/CD8+ T cells producing IL-2 and/or IFNgamma following ex-vivo stimulation with HIV-1 peptide pools		at weeks 26 and 28, 48 and 72	No
Secondary	Cellular responses: number of different epitopes that can be characterised		to be determined at a later stage	No
Secondary	Antibody responses		to be determined at a later stage	No
Secondary	All grade 1 and 2 adverse events		within 72 weeks	No
Secondary	All events including those considered unrelated		within the 72 weeks	No